Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years [7]

South African Medical Journal

Volumn 96, Issue 12 I, 2006, Pages 1249-1251

  Rawoot, A ^a   Little, F ^b   Heckmann, J M ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE;

BRAIN LYMPHOMA; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; DRUG FATALITY; DRUG MEGADOSE; FEMALE; HUMAN; KIDNEY CANCER; LETTER; LONG TERM CARE; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHODGKIN LYMPHOMA; RECTUM CANCER; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK FACTOR; STOMACH CANCER; TESTIS CANCER; THYMOMA; TREATMENT DURATION; UTERINE CERVIX CANCER;

ADULT; AZATHIOPRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MEDICAL RECORDS; MIDDLE AGED; MYASTHENIA GRAVIS; NEOPLASMS; RISK FACTORS; SOUTH AFRICA;

EID: 33846105723     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (14)

1. Connell WR, Kamm MA, Michael A. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-1252.
2. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis. Arthritis Rheum 2004; 50:1740-1751.
3. Hohlfield R, Michels M, Heininger K, et al. Azathioprine toxicity during long-term immunosuppression of generalised myasthenia gravis. Neurology 1988; 38: 258-261.
4. Herrlinger U, Weller M, Dichgans J, et al. Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis. Ann Neurol 2000; 47: 682-683.
5. Mqoqi N, Kellet P, Madhoo J, et al. Cancer in South Africa: Incidence of Histologically Diagnosed Cancer in South Africa, 1998-1999. National Cancer Registry Report. Johannesburg: NHLS, 2004.
6. Evoli A, Batocchi P, Tonali P, et al. Risk of cancer in patients with myasthenia gravis. Ann N Y Acad Sci 1998; 841: 742-745.
7. Barthelmes L, Thomas KJ, Scale JRC. Prostatic involvement of a testicular lymphoma in a patient with myasthenia gravis on long-term azathioprine. Leuk Lymphoma 2002; 43: 2425-2426.
8. Levin N, Abramsky O, Lassos A, et al. Extrathymic malignancies in patients with myasthenia gravis. J Neurol Sci 2005; 237(1-2): 39-43.
9. Fraser AG, Orchard TR, Robinson M, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002; 16: 1225-1232.
10. Nero P, Rahman A, Isenberg DA. Does long-term treatment with azathioprine predispose to malignancy and death in patients with SLE. Ann Rheum Dir 2004; 63: 325-326.
11. Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in MS: A case-control study. Neurology 1996; 46: 1607-1612.
12. Asten P, Barrel J, Symmons D. Risk of developing certain malignancies related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999; 26: 1705-1714.
13. Monden Y, Umyama T, Kimara S, et al. Extrathymic malignancy in patients with myasthenia gravis. Eur J Cancer 1991; 27: 745-747.
14. Vincent A, Clover L, Buckley J, et al. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003; 74: 1105-1108.